Clinical
features and prognostic factors of breast cancer
at Jordan
..........................................................................................................................
Dr Ali Al Obose* FRCS
Dr Osama Abu Salem* MRCSI
Dr Maysoun Alrabayha**
Dr Khalid Alghzawi
*General Surgeon at RMS
**Histopathologist at RMS
Address correspondence to:
Dr Osama Abu Salem, Email: Osamaabusalem@hotmail.com
..........................................................................................................................
|
ABSTRACT
Background:
Data on the clinical profile of breast
cancer from Jordan is scant, due to different
factors such as lack of proper statistical
centers, different lifestyle, and different
socio-demographic structures.
Aim: To analyze the clinical presentation
and outcome of Jordanian patients with breast
cancer.
Materials and
methods: Data from 184 patients registered
and treated at different Royal Medical Services
Hospitals in Jordan from January 2002 to
December 2005 were analyzed. The analysis
concentrates on age, site, lymph nodes status,
grade and type of the breast cancer found
in Jordanian patients.
Results: The
median age was 52.5 years and 54% of patients
were pre-menopausal. Ninety-six per cent
(177) patients presented with a lump. Stages
1 (14/184), Stage 2 (111/184), and Stage
3 comprised (59/184). Right breast involved
in breast cancer was (93 /184), left breast
involvement (90/184) and one case had a
bilateral involvement. Most patients who
needed chemotherapy were prescribed Tamoxifen
for 5 years. The majority (86.4%) had a
lump size > two cm.
Conclusions:
- The study's results
indicated that breast cancer prognosis
in Jordan remains poor, primarily due
to late diagnosis.
- Since breast conservation
protocols yield results similar to mastectomy,
its use should be extended. Search for
biological prognostic indicators should
continue for their potential use as guides
for treatment decisions.
- Tumor size, grade
and year of diagnosis all have significant
constant effects on disease-specific survival
in breast cancer, while the effects of
age at diagnosis and disease stage have
significant effects that vary over time.
- The histologic
type is important to consider in the prognosis
and treatment of women diagnosed with
breast cancer.
- Future studies
of survival of node-negative patients
should include information on co-morbidity
and treatment
|
Breast
cancer is the most common cancer and the second
leading cause of cancer death among women in general;
annual breast cancer deaths are exceeded only
by those for lung cancer. (1)
The traditional diagnostic approach to breast
lumps include physical examination, ultrasound
and a mammogram screening procedure. These diagnostic
procedures have a relatively low sensitivity regarding
definite malignant small breast lumps and have
largely been replaced by cytological lump evaluation.
Breast cancer is one of the most common malignancies
in women and the incidence has been increasing.
Cytology play an important role not only in the
diagnosis of breast lesions, but also in keeping
the benign -to -malignant biopsy ratio low, so
that unnecessary surgery is not performed. However,
breast carcinomas do not always show every feature
of malignancy. The well- differentiated or low-grade
carcinomas are often difficult to differentiate
from benign cells .It may be helpful to consider
the clinical and radiological findings.
Conservative treatment of
multifocal breast cancers, which can be completely
removed by a single lumpectomy, seems, when technically
feasible, an alternative to mastectomy. The increasing
prevalence of breast cancer in our society has
produced an ever-greater demand for new diagnostic
and therapeutic technologies. Today, patients
ask not only that these new technologies offer
improved diagnostic and treatment capabilities
but also that the procedures are convenient, cost-effective,
and less invasive than before. Other diagnostic
tools, such as sonography, mammography, magnetic
resonance imaging and scintimammography, are now
available .The additional information afforded
by these technologies is intended to limit the
number of patients who need further evaluation
with breast biopsy. Early-onset breast cancer
may differ with respect to etiology, clinical
features and outcome compared with breast cancer
in older women.
Clinically most of the patients with malignant
breast lump had a palpable mass, which signifies
the role of routine self-examination and screening
programs.
Late diagnosis is a major
factor for increased mortality as the majority
of the patients present in advanced or metastatic
stage. This is primarily attributed to lack of
access to medical facilities, virtually non-existent
breast cancer screening programs, lack of awareness
and social-cultural attitudes. . A recent meta-analysis
of the breast cancer screening trials indicates
that screening reduces the mortality rate by approximately
25% (2).
Data
from 184 patients registered and treated at different
Royal Medical Services Hospitals in Jordan from
2002 through 2005 were analyzed. The analysis
concentrated on age, site, lymph nodes status,
grade and type of the breast cancer, found in
Jordanian patients.
Case records of all the female
patients presented at the surgical Clinic in the
Royal Medical Services Hospitals over a four-year
period from January 2002 to December 2005, were
retrieved. EBC (Early Breast Cancer) was defined
as tumors of less than five centimeters (T1, T2),
with either impalpable (N0) or palpable (N1) but
not fixed lymph nodes, with no evidence of distant
metastases (M0), corresponding to Stages I. Patients
with tumors more than five cm (T3) were included
if they had N0 M0 disease; Stage IIb. All EBC
cases with pathological confirmation either by
fine needle aspiration cytology or core biopsy
and who had been treated by at least one mode
of treatment (surgery, chemotherapy or radiotherapy)
were included in the analysis.(Table
1.). Data from 184 patients was thus analyzed.
All patients were followed up every three months
after discharge from the hospital, following the
initial treatment.
The
median age was 52.5 years and 54% of patients
were pre-menopausal. 5% have unknown menopausal
status and 41% had a post menopausal status. Ninety-six
per cent (177) patients presented with a lump.
Stages 1 (14/184), Stage 2 (111/184), and Stage
3 comprised (59/184). Right breast involved in
breast cancer was (93 /184), left breast involvement
(90/184) and one case had a bilateral involvement.
Most patients who needed chemotherapy were prescribed
Tamoxifen for 5 years.
Median
ages at menarche and menopause were 14 years (range
12-17 years) and 46 years (36-56 years), respectively.
177 (96%) patients presented with breast lump.
The majority (86.4%) had a lump size > two
cm. 77 (15.8%) had pain and 24 (4.9%) additionally
had nipple discharge.
All patients underwent surgery;
either a breast-conserving surgery (BCS) was carried
out or simple mastectomy with axillary clearance
was performed. Invasive ductal carcinoma was the
commonest histology in 151 (82.1%) patients followed
by invasive lobular carcinoma in 18 (9.7%), mixed
type 12(6.5%) and medullary carcinoma in three
(1.6%).
Adjuvant radiotherapy was given
to some patients; indications included T3 tumor
size, = 4 positive axillary nodes, (Table
2), positive margins, and BCS. Chemotherapy
was administered to other women. Most of the patients
were given CMF regimen at the oncology clinic.
Breast
cancer is a major cause of cancer deaths in women
and is increasing in incidence. There appears
to be a leveling off in the incidence of breast
cancer; previously the incidence had been increasing.
A typical pathology report should indicate the
type of breast cancer, the histologic grade, the
size, and a comment on the surgical margins. In
addition, depending upon the case, ancillary studies
examining for estrogen and progesterone receptors
may be ordered. The age-specific incidence rate
curve for breast carcinoma overall increases rapidly
until age of about 52 years, and then continues
to increase at a slower rate for older women.
Breast cancer clinical research
An important goal is to analyze how factors are
seen to affect the disease process. Meanwhile,
the disease progression is not fully modeled using
standard analysis since transitions between intermediate
events such as local-regional recurrences or metachronous
contra lateral breast cancer are not considered.
In the present study
Breast cancer was usually self-diagnosed and tumors
were > 2 cm at presentation in some of the
cases, suggesting the possibilities of a delay
in diagnosis, more aggressive tumors or both.
Menopause did not seem to have any effect on Breast
carcinoma as evidenced by steadily rising rates
at all ages.
The 3 known causes of human
breast cancer, ionizing radiation, exogenous ovarian
hormones and beverage alcohol, offer some preventive
possibilities but do little to explain the epidemiologic
features of the majority of cases of the disease
that occur in their absence (3)
There is no evidence that
detection bias plays a major role, and although
the right breast is slightly larger, on average,
than the left, there is little evidence that breast
size is associated with breast cancer risk. The
reason for the right-sided excess among women
in our study remains unclear.
Breast carcinoma is an unpredictable
disease in the sense that some patients may present
with relatively early disease and die of widespread
metastases within six months to one year, while
others present with fairly advanced disease and
yet survive longer (4). The various histologic
types of breast cancer exhibit differences in
regard to relative frequency, site pattern within
the breast, and patient survival.
Young patients with breast
cancer had the worst histopathological features
and the worst survival rate compared to their
older counterparts. Age was an independent significant
prognostic factor for relapse. (5). Tumor size,
grade, race of patient, and year of diagnosis
all have significant constant effects on disease-specific
survival in breast cancer, while the effects of
age at diagnosis and disease stage have significant
effects that vary over time. (6)
Younger patients as a group
have more aggressive and advanced breast cancer
at presentation compared with older patients.
Considered in a multivariate model, together with
other variables, age does not provide independent
prognostic information and should not be used
alone for management decisions (7). Young breast
cancer patients have poorer outcomes, which are
in part attributed to later stage disease, more
aggressive tumors, and less favorable receptor
status. There still appears to be other important
factors that are contributing to the worse outcomes
for these young patients, such as socio-economic
status. Physicians need to have heightened awareness
when evaluating this population, and increasingly
efficacious adjuvant therapies need to be developed.
-The outcome of these patients may be improved
by patient education and availability of better
health care facilities
-Axillary ultrasonography is
increasingly being used to improve the staging
of breast cancer patients who have negative axillary
lymph nodes on physical examination. (8) This
approach has a number of advantages. First, node-positive
patients identified with ultrasonography can be
referred for axillary dissection, without the
need for sentinel lymph node (SLN) staging. (9)
The probability of death from breast cancer exceeded
that from all other causes for patients diagnosed
with localized disease before age 50 years, with
regional disease before age 60 years, and with
distant disease at any age. (10) There is little
evidence that breast size is associated with breast
cancer risk. (11)
Patient care decisions occur in the context of
breast cancer and other age-related conditions.
Co-morbidity in older patients may limit the ability
to obtain prognostic information (i.e., axillary
lymph node dissection), tends to minimize treatment
options (e.g., breast-conserving therapy), and
increases the risk of death from causes other
than breast cancer. (12). In general breast cancer
is a major public health problem in Jordan. Late
presentation is a major concern, as large numbers
of early breast cancer patients are still diagnosed
in clinical Stage II. Patient preference for mastectomy
is an important reason for the under-utilization
of breast conservation therapy. Education/awareness
campaigns, improvement of socio-economic conditions,
better access to diagnostic resources, availability
of higher standards of health care, use of breast
self-examination, and screening mammography if
implemented nationally would go a long way towards
increasing early diagnosis and improved survival
with a consequent possible rise in incidence of
early cases as is happening in the West.
In
our study there was no impact on recurrence of
breast cancer with regard to size, age, menopausal
status, nodal status, histologic subtype, adjuvant
therapy, or extent of surgery.
- The study's results indicated
that breast cancer prognosis in Jordan remains
poor primarily due to late diagnosis.
- Since breast conservation
protocols yield results similar to mastectomy,
its use should be extended. Search for biological
prognostic indicators should continue for their
potential use as guides for treatment decisions.
- Mammogram is a valuable
tool in early detection of breast cancer; this
is especially in bilateral breast cancer, which
is invariably advanced when diagnosed.
- Tumor size, grade and year
of diagnosis all have significant constant effects
on disease-specific survival in breast cancer,
while the effects of age at diagnosis and disease
stage have significant effects that vary over
time.
- Future studies of survival
of node-negative patients should include information
on co morbidity and treatment.
- We conclude that histologic
type is important to consider in the prognosis
and treatment of women diagnosed with breast
cancer.
|
|
Table
1. Patient and tumor characteristics
|
|
Characteristic |
No.
(%) of patients
|
|
Age, mean (range)
|
52.5y
|
|
Primary tumor stage
|
|
|
Tx
|
1
|
|
Tis
(± microinvasion)
|
11
|
|
T1
|
78
|
|
T2
|
55
|
|
T3
|
23
|
|
T4
|
16
|
|
Pathologic nodal
stage
|
|
|
N0
|
64
|
|
N1
|
120
|
|
No. Of nodes recovered,
mean (range) a
|
18 nodes
|
|
Method of diagnosis
|
|
|
Fine-needle
aspiration
|
29
|
|
Core
needle biopsy
|
140
|
|
Excisional
biopsy
|
21
|
|
Incisional
biopsy
|
4
|
|
Interval between
Breast and axillary ultrasonography+
/-mammography and surgery
|
|
|
<1
mo
|
164
|
|
1
< 3 mo
|
13
|
|
3
< 6 mo
|
7
|
|
A Data from 184
patients with complete axillary
dissection.
|
back
to text
| Table
2. Lymph Nodes Status in patients
with breast cancer |
|
Years
|
2002
|
2003
|
2004
|
2005
|
Total
|
|
Positive LN
|
22
|
33
|
42
|
23
|
120
|
|
Negative LN
|
9
|
20
|
17
|
18
|
64
|
back
to text
|
- Cancer. 1995 Jan 1; 75(1
Suppl): 257-69. Breast cancer. Berg JW, Hutter
RV. Department of Pathology and Preventive Medicine,
University of Colorado, Boulder.
- Jatoi I: The case against
mammographic screening for women in their forties.
In Jatio I (ed.): Breast Cancer Screening Austin,
TX, Landes Bioscience, pp 35-49, 1997.
- Int J Cancer. 2005 Dec 15;
118(10): 2373-2378 Epidemiology and the causes
of breast cancer.Macmahon B. Harvard School
of Public Health, Boston, MA, USA. PMID: 16358260
[Pub Med - as supplied by publisher]
- Niger J Med. 2005 Jan-Mar;
14(1): 72-6. Histopathological characteristics
of female breast carcinomas seen at the University
of Port Harcourt Teaching Hospital, Port Harcourt
Nigeria.Gogo-Abite M, Nwosu SO. Department of
Anatomical Pathology, University of Port Harcourt
Teaching Hospital, Port Harcourt, Rivers State,
Nigeria.
- J Surg Oncol 2000 Aug; 74(4):
267-72.Prognostic significance of young age
in breast cancer.Yildirim E, Dalgic T, Berberoglu
U.
Department of Surgery, Ankara Oncology Hospital,
Ankara, Turkey.
- Breast Cancer Res Treat.
2005 Jan; 89(1): 47-54.The effect of age, race,
tumor size, tumor grade, and disease stage on
invasive ductal breast cancer survival in the
U.S. SEER database. Rosenberg J, Chia YL, Plevritis
S. Department of Radiology, Stanford University,
Stanford, CA, USA.
- Arch Surg 1994 May; 129(5):
483-7; discussion 487-8. Age does not predict
breast cancer outcome. Crowe, Gordon NH, Shenk
RR, Zollinger RM Jr, Brumberg DJ, Shuck JM.Department
of Surgery, Case Western Reserve University
School of Medicine, Cleveland, Ohio.
- Herrada J, Iyer RB, Atkinson
EN, et al. Relative value of physical examination,
mammography, and breast sonography in evaluating
the size of the primary tumor and regional lymph
node metastases in women receiving neoadjuvant
chemotherapy for locally advanced breast carcinoma.
Clin Cancer Res 1997; 3: 1565-9.
- de Kanter AY, van Eijck
CH, van Geel AN, et al. Multicentre study of
ultrasonographically guided axillary node biopsy
in patients with breast cancer. Br J Surg 1999;
86: 1459-62.
- J Natl Cancer Inst.2004
Sep 1; 96(17): 1311-21.Probabilities of death
from breast cancer and other causes among female
breast cancer patients. Schairer C, Mink PJ,
Carrll L.Devesa SS. Division of Cancer Epidemiology
and Genetics, National Cancer Institute, National
Institutes of Health, Bethesda, MD, USA.
- Cancer causes control.1996
Sep: 7(5): 539-43. Laterality of breast cancer
in the United States. Wies HA, Devesa SS, Brinton
LA. Division of Cancer Epidemiology and Genetics,
National Cancer Institute,
Bethesda, MD 20892-7374, USA.
- JAMA.2001 Feb 21: 285(7):
885-92Effect of age and co morbidity in postmenopausal
breast cancer patients aged 55 years and older.Yancik
R, Wesley MN, Ries LA, Havlik RJ, Edwards BK,
Yates JW. Cancer Section, Geriatrics Program,
National Institute on Aging, National Institutes
of Health, Bethesda, MD 20892-9205, USA.
|